Natera, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| NTRA | RVTY | ILMN | NEO | GH | BLLN | |
|---|---|---|---|---|---|---|
| Market cap | 57.34B | 17.36B | 41.78B | 2.08B | 21.85B | 4.39B |
| P/E (TTM) | — | 74.5 | 51.6 | — | — | 147.7 |
| Forward P/E | -2,014.0 | 26.4 | 45.2 | 47.8 | -394.5 | 62.7 |
| Price/book | 31.4 | 2.4 | 14.7 | 2.6 | -97.6 | 8.1 |
| Dividend yield | — | 0.18% | — | — | — | — |
| 1-year change | +130.07% | +69.47% | +192.72% | +75.05% | +171.29% | −14.57% |
| Today | −0.73% | +0.93% | −0.54% | −0.92% | −2.79% | −5.12% |
The closest companies by business and industry (Diagnostics & Research). Prices may be delayed up to 15 min.
Latest news
All NTRA news ›Top Five: Natera MCED Breakthrough Device, Caribou Demise, More
Top Five Articles Last Week: Natera MCED Designated Breakthrough Device, Caribou Bio Demise, More GenomeWeb Top Five Articles Last Week: Natera MCED Designated Breakthrough Device, Caribou Bio Demise, More
Four Signatera Abstracts Selected for Oral Presentations at ASTRO 2026 – Natera
OncoDaily is a specialized news and information platform that provides daily updates on oncology research, treatments, clinical trials, and advancements in cancer care. It serves healthcare professionals, researchers, and patients by…
Jordan Stricker: Natera’s Multi-Cancer Early Detection Assay Receives FDA Breakthrough Device Designation
Jordan Stricker, Director of Strategic Oncology Collaborations at Natera, shared on LinkedIn: “Today the FDA granted Breakthrough Device designation to Natera’s multi-cancer early detection assay. That is not a marketing authorization. It…
Natera and Susan G. Komen Partner to Support People Impacted by Breast Cancer
Natera, shared on X: “Natera is proud to be the 2026 Premier National Series Sponsor of the Susan G. Komen Race for the Cure and MORE THAN PINK Walk events. So far, we’ve walked with you at the: This partnership combines Natera’s…
Why Natera (NTRA) Stock Is Up Today
Barchart.com
Natera receives FDA breakthrough designation for multi-cancer blood test
The FDA reviewed data from 12 cancer types, but Natera disclosed no performance figures or date for a marketing submission. Priority access to FDA feedback and review opened for a multi-cancer blood test on Friday after Natera, Inc.…
Natera, Alliance Foundation Trials Launch Phase 3 Trial for Breast Cancer Treatment Strategy
Natera and research organization Alliance Foundation Trials have launched a phase 3 trial evaluating a novel molecular residual disease-guided treatment strategy for patients with intermediate and... Healthcare Facilities & Services…
Natera: Priced To Perfection Amidst Rising Competitive Threats
Natera is rated Sell, as its valuation is stretched, with perfect execution priced in, despite looming competitive threats. Click to read more about NTRA. Anchiy/E+ via Getty Images Natera (NTRA) was founded in 2003 and is based in Austin,…
Neumora Therapeutics (NASDAQ:NMRA) Cut to Strong Sell at Wall Street Zen
Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) was downgraded by investment analysts at Wall Street Zen from a "sell" rating to a "strong sell" rating in a report issued on Saturday, Wall Street Zen reports. Get Our Latest Stock…
Natera, Inc. : Insider Transactions
Follow insider transactions on Natera, Inc. in real time. Filter by importance or transaction type and analyze the history on MarketScreener. Insider Transactions Natera, Inc. Healthcare Facilities & Services Latest insider transactions…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
-
marketscreener.com11
-
cnbc.com2
-
stocktitan.net2
-
barchart.com1
-
claimdepot.com1
Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 27 articles, not a forecast.